All In Biotech

Drug Trial Radar · NCT06169319

A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)

A Phase 2, Double-blind, Randomized, Placebo-controlled, Dose-ranging Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fasciitis (PFA)

Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

231

Actual

Start

Jan 3, 2024

Primary completion

Sep 30, 2024

Study completion Sep 30, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.

Conditions

  • Plantar Fasciitis

Interventions

  • Collagenase Clostridium Histolyticum (CCH)Biological

    Biologic: Intrafascial injection

  • PlaceboBiological

    Intrafascial injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline at Week 12 in the Weekly Mean of the Average Daily (24-hour) Pain (ADP) Score as Measured on the Pain Intensity Numeric Rating Scale (NRS)Time frame: Baseline, Week 12

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Endo Site 8

    Tucson, Arizona

  • Endo Site 20

    Castro Valley, California

  • Endo Site 13

    Corona, California

  • Endo Site 6

    Encinitas, California

  • Endo Site 11

    Fresno, California

  • Endo Site 16

    Los Angeles, California

  • Endo Site 40

    Los Angeles, California

  • Endo Site 21

    San Francisco, California

  • Endo Site 10

    Tarzana, California

  • Endo Site 37

    Coconut Creek, Florida

  • Endo Clinical Site 3

    Pinellas Park, Florida

  • Endo Site 14

    Sweetwater, Florida

  • Endo Site 7

    Lawrenceville, Georgia

  • Endo Site 23

    Stonecrest, Georgia

  • Endo Site 31

    North Chicago, Illinois

  • Endo Site 28

    O'Fallon, Illinois

  • Endo Site 33

    Overland Park, Kansas

  • Endo Site 35

    Shreveport, Louisiana

  • Endo Clinical Site 2

    Pasadena, Maryland

  • Endo Site 19

    Grand Rapids, Michigan

  • Endo Site 27

    Missoula, Montana

  • Endo Site 38

    Westwood, New Jersey

  • Endo Site 25

    Moore, Oklahoma

  • Endo Site 39

    Portland, Oregon

  • Endo Site 36

    Malvern, Pennsylvania

  • Endo Clinical Site 4

    Bedford, Texas

  • Endo Site 24

    Burleson, Texas

  • Endo Site 17

    Dallas, Texas

  • Endo Site 26

    Dallas, Texas

  • Endo Site 18

    Dallas, Texas

  • Endo Site 30

    Fort Worth, Texas

  • Endo Clinical Site 1

    Georgetown, Texas

  • Endo Site 15

    Houston, Texas

  • Endo Site 9

    McAllen, Texas

  • Endo Site 34

    San Antonio, Texas

  • Endo Site 22

    San Antonio, Texas

  • Endo Clinical Site 5

    Salt Lake City, Utah

  • Endo Site 32

    Newport News, Virginia

  • Endo Site 12

    Suffolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.